Epidemiology of the metabolic syndrome in the USA (Q28298801)

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Non-alcoholic fatty liver disease and the metabolic syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Pathogenesis of non-alcoholic steatohepatitis: human data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Prevalence of the metabolic syndrome and overweight among adults in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2010.00469.X